Charles River initially unveiled a plan to adopt new alternative methods (NAMs), like computer models and human organoids, in ...

The U.S. government has pulled the rug out from under Pluri Biotech’s PLX-R18 cell therapy. | The U.S. government has pulled ...

VelaVigo Bio has landed its second deal in six months, offloading ex-China rights to a bispecific to Ollin Biosciences for up ...

Alis Biosciences has made a pitch to the hundreds of biotechs that are valued at less than the cash they have in the bank.

Biotechs will need to be strategic to achieve “tariff-era success” as the sector enters an “America-first resurgence,” ...

After mass layoffs, the FDA has started missing certain deadlines, pushing one biopharma to delay a phase 3 trial and ...

The material is employed in a range of Edwards’ surgical and transcatheter valves, including versions of the Inspiris, Mitris ...

Eli Lilly has met its goal of achieving semaglutide-like efficacy with an oral GLP-1 drug. | Eli Lilly has met its goal of ...

The U.S. government continues to end contracts related to the $5 billion Project NextGen initiative, this time terminating ...

Precision Neuroscience has obtained an FDA clearance for a crucial piece of its plans for a full brain-computer interface ...

Novartis has terminated a phase 2 trial evaluating an investigational ADAMTS-5 inhibitor for patients with osteoarthritis ...

Sanofi is continuing to splash the cash for autoimmune and immunology assets this spring by penning a new deal with ...